BMO Capital Markets reaffirmed their buy rating on shares of AstraZeneca (NYSE:AZN) in a research note issued to investors on Sunday, February 4th.
Other research analysts also recently issued research reports about the company. Zacks Investment Research raised AstraZeneca from a sell rating to a hold rating in a research note on Monday, January 22nd. ValuEngine raised shares of AstraZeneca from a buy rating to a strong-buy rating in a research report on Saturday, February 3rd. Leerink Swann restated a market perform rating and set a $36.00 price target (up from $33.00) on shares of AstraZeneca in a report on Thursday, January 18th. Citigroup upgraded AstraZeneca to a buy rating in a report on Wednesday, October 18th. Finally, Cowen reiterated a hold rating and issued a $37.00 target price on shares of AstraZeneca in a report on Tuesday, October 17th. Three investment analysts have rated the stock with a sell rating, eight have given a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company currently has an average rating of Hold and a consensus price target of $35.20.
AstraZeneca (AZN) opened at $34.09 on Friday. The company has a market cap of $85,127.08, a price-to-earnings ratio of 7.85, a price-to-earnings-growth ratio of 2.03 and a beta of 0.70. AstraZeneca has a fifty-two week low of $28.43 and a fifty-two week high of $36.70. The company has a debt-to-equity ratio of 0.93, a current ratio of 0.80 and a quick ratio of 0.62.
AstraZeneca (NYSE:AZN) last posted its quarterly earnings data on Friday, February 2nd. The company reported $1.30 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $0.44 by $0.86. The business had revenue of $5.78 billion during the quarter, compared to analysts’ expectations of $5.49 billion. AstraZeneca had a net margin of 13.36% and a return on equity of 34.74%. AstraZeneca’s revenue was up 3.4% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.21 earnings per share. equities research analysts predict that AstraZeneca will post 1.67 EPS for the current year.
The business also recently announced a semiannual dividend, which will be paid on Monday, March 19th. Shareholders of record on Friday, February 16th will be issued a dividend of $0.95 per share. This represents a yield of 5.62%. The ex-dividend date of this dividend is Thursday, February 15th. AstraZeneca’s payout ratio is presently 57.81%.
Several institutional investors and hedge funds have recently modified their holdings of the company. Fisher Asset Management LLC lifted its position in AstraZeneca by 2.7% in the 4th quarter. Fisher Asset Management LLC now owns 11,917,332 shares of the company’s stock worth $413,531,000 after buying an additional 315,759 shares during the last quarter. Wells Fargo & Company MN increased its stake in AstraZeneca by 7.6% in the 3rd quarter. Wells Fargo & Company MN now owns 4,406,824 shares of the company’s stock worth $149,303,000 after purchasing an additional 310,389 shares during the period. Ameriprise Financial Inc. increased its stake in AstraZeneca by 7.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 3,026,781 shares of the company’s stock worth $102,643,000 after purchasing an additional 199,519 shares during the period. Capital Bank & Trust Co increased its stake in AstraZeneca by 2.1% in the 3rd quarter. Capital Bank & Trust Co now owns 2,730,208 shares of the company’s stock worth $92,499,000 after purchasing an additional 57,353 shares during the period. Finally, Dimensional Fund Advisors LP increased its stake in AstraZeneca by 18.3% in the 3rd quarter. Dimensional Fund Advisors LP now owns 2,558,882 shares of the company’s stock worth $86,695,000 after purchasing an additional 395,699 shares during the period. Hedge funds and other institutional investors own 14.75% of the company’s stock.
WARNING: “AstraZeneca (NYSE:AZN) Rating Reiterated by BMO Capital Markets” was published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this piece of content on another site, it was copied illegally and republished in violation of U.S. and international copyright and trademark legislation. The original version of this piece of content can be viewed at https://www.dispatchtribunal.com/2018/02/13/astrazeneca-azn-rating-reiterated-by-bmo-capital-markets.html.
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on discovery and development of products, which are then manufactured, marketed and sold. The Company focuses on three main therapy areas: Oncology, Cardiovascular & Metabolic Disease (CVMD) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience.
Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.